RemeGen Fast-Tracks Potential World-First BLys/APRIL Agent For gMG In Global Phase III Trial

RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.

PatientRecruitment — RemeGen is pulling out all the stops to enroll patients in a global Phase III clincial trial in generalized myasthenia gravis. • Source: Shutterstock

Despite struggling with the financial burden, Chinese firm RemeGen is pulling out all the stops for its ongoing global Phase III RemeMG study to repeat the positive safety and efficacy outcomes from a similar China-only study with telitacicept, its backbone asset for autoimmune disorders, in generalized myasthenia gravis (gMG).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC

17 Apr 2025

• By Dexter Jie Yan

While Henlius Biotech’s PD-L1-targeting antibody-drug conjugate HLX43 is struggling to catch up with Pfizer’s PF-08046054, the global frontrunner in the space, a key differentiation of the China-originated asset could lie in PD-L1-negative patients.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

15 Apr 2025

• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Orphans Cling On To Growth Advantage As Market Share Heads Towards 20%

03 Apr 2025

• By Alexandra Shimmings

It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.